Core Insights - NeuroOne Medical Technologies Corporation is addressing the significant unmet need for non-pharmaceutical treatments for epilepsy, targeting the approximately one million patients who do not respond to current antiseizure medications [2][3]. Company Overview - NeuroOne has developed the OneRF™ ablation system, which is the first FDA 510(k)-cleared device capable of recording brain activity and performing RF ablation simultaneously [4]. - The OneRF™ system includes an electrode for monitoring brain activity, a temperature probe, and a radio frequency heat generation system, ensuring safe ablation temperatures [4][5]. Innovation and Impact - The OneRF™ system allows for a single hospitalization procedure, eliminating the need for multiple invasive surgeries and enabling real-time monitoring of the ablation's success [5][6]. - A case study highlighted a teenage patient who experienced significant seizure reduction after using the OneRF™ system, showcasing its potential to improve patients' quality of life [6]. Industry Context - Approximately 50 million people worldwide are affected by epilepsy, with over three million diagnosed in the US alone [2]. - The healthcare industry is increasingly focusing on innovative technologies that can provide more effective and personalized treatment options for neurological disorders [7]. Future Directions - NeuroOne is also exploring applications for other neurological conditions, including Parkinson's disease, chronic pain, and mood disorders, indicating a broader potential impact on patient care and procedural costs [9].
NeuroOne CEO Joins Today's Marketplace To Discuss The Latest Treatments for Epilepsy